A Diagnostics & Imaging Week

Caliper Life Sciences (Hopkinton, Massachusetts) and AntiCancer (San Diego) reported that they have entered into an agreement to establish a cross-licensing relationship and end all outstanding patent litigation between the two companies.

Under the new arrangement:

• Caliper acquires the right to sublicense AntiCancer’s fluorescent protein optical imaging patents to third-parties, alongside Caliper’s own portfolio of in vivo fluorescent and bioluminescent optical imaging patents;

• AntiCancer acquires the right to sublicense Caliper’s optical imaging patents, in the field of fluorescent protein imaging, to a specified annual number of third parties throughout the life of the agreement, alongside AntiCancer’s own fluorescent protein optical imaging patents; and

• Each company receives a royalty-free license from the other for internal and contract research operations.

Caliper and AntiCancer will share in any revenues generated by the licensing of their imaging technologies in the field of fluorescent protein imaging. No other payments will be made for either the settlement or cross-licensing agreements.